fraxinellone has been researched along with Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, X; Li, MY; Ma, J; Mi, C; Wang, JY; Wang, Z; Xing, Y; Zhang, ZH; Zuo, HX | 1 |
1 other study(ies) available for fraxinellone and Neoplasms
| Article | Year |
|---|---|
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Benzofurans; Cell Line, Tumor; Cell Movement; Female; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Neoplasms; STAT3 Transcription Factor | 2018 |